iShares Core High Dividend ETF(HDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HDV iShares Core High Dividend ETF

Not Yet Opened 06-11 16:00:00 EDT

27.63

-0.05

-0.18%

盘后27.54

-0.09-0.33%

19:55 EDT

High27.88	Low27.61	Vol2.64M
Open27.85	D1 Closing27.68	Amplitude0.98%
Mkt Cap13.59B	Tradable Cap13.59B	Total Shares491.90M
T/O73.35M	T/O Rate0.54%	Tradable Shares491.90M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"HDV","market":"US","secType":"STK","nameCN":"iShares Core High Dividend ETF","latestPrice":27.63,"timestamp":1781208000000,"preClose":27.68,"halted":0,"volume":2640550,"hourTrading":{"tag":"盘后","latestPrice":27.54,"preClose":27.63,"latestTime":"19:55 EDT","volume":2011,"amount":55511.4999,"timestamp":1781222144551,"change":-0.09,"changeRate":-0.003257,"amplitude":0.005429},"delay":0,"changeRate":-0.001806358381502916,"floatShares":491900000,"shares":491900000,"eps":0,"marketStatus":"Not Yet Opened","change":-0.05,"latestTime":"06-11 16:00:00 EDT","open":27.85,"high":27.88,"low":27.61,"amount":73350180.1846,"amplitude":0.009754,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781251200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":27.68,"sharesOutstanding":98450000,"nav":27.674945,"aum":13658969104.75,"dividendRate":0.028654,"bidAskSpread":0.000361,"preHourTrading":{"tag":"盘前","latestPrice":27.85,"preClose":27.68,"latestTime":"09:28 EDT","volume":2117,"amount":58899.502134999995,"timestamp":1781184527026,"change":0.17,"changeRate":0.006142,"amplitude":0.017341},"postHourTrading":{"tag":"盘后","latestPrice":27.54,"preClose":27.63,"latestTime":"19:55 EDT","volume":2011,"amount":55511.4999,"timestamp":1781222144551,"change":-0.09,"changeRate":-0.003257,"amplitude":0.005429},"volumeRatio":0.85522,"impliedVol":0.1702,"impliedVolPercentile":0.9004},"requestUrl":"/m/hq/s/HDV/wiki","defaultTab":"wiki","newsList":[{"id":"2639561638","title":"Assembly Biosciences Announces Upcoming Investor Conference Presentations","url":"https://stock-news.laohu8.com/highlight/detail?id=2639561638","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639561638?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:05","pubTimestamp":1779998700,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., May  28, 2026  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3303246/16259/en/Assembly-Biosciences-Announces-Upcoming-Investor-Conference-Presentations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASMB","BK4588","HDV","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638571480","title":"Aligos Therapeutics Presents Positive Data at the EASL Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638571480","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638571480?lang=en_us&edition=fundamental","pubTime":"2026-05-27 14:30","pubTimestamp":1779863400,"startTime":"0","endTime":"0","summary":"Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoirData on the preclinical characteristics of the Aligos/Amoytop ASO progra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301633/0/en/Aligos-Therapeutics-Presents-Positive-Data-at-the-EASL-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HDV","ALGS","BK4561","BK4200","ASO","BK4585","BK4588","BK4233","BK4141","BK4505","BK4139","UK","BK4205","BK4528","NA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638405265","title":"Press Release: Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2638405265","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638405265?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:05","pubTimestamp":1779825900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., May 26, 2026  -- Assembly Biosciences, Inc. , a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the closing of its previously announced underwritten registered offering of 3,924,624 shares of its common stock at an offering price per share of common stock of $26.50, which includes the exercise in full by the underwriters of their option to purchase 566,040 additional shares of common stock. In addition, and in lieu of common stock, Assembly Bio sold to a certain existing investor pre-funded warrants to purchase up to an aggregate of 415,000 shares of common stock at an offering price per pre-funded warrant of $26.499, which represents the per share offering price of the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds to Assembly Bio from this offering were approximately $115.0 million before deducting underwriting discoun","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","HDV","ASMB","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637346085","title":"FDA approves Gilead’s Hepcludex injection to treat chronic HDV infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2637346085","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637346085?lang=en_us&edition=fundamental","pubTime":"2026-05-23 01:25","pubTimestamp":1779470743,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration approved Hepcludex injection to treat chronic hepatitis delta virus infection in adults without cirrhosis or ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-approves-gileads-hepcludex-injection-to-treat-chronic-hdv-infection-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-approves-gileads-hepcludex-injection-to-treat-chronic-hdv-infection-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HDV","BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637163903","title":"Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2637163903","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637163903?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:00","pubTimestamp":1779447600,"startTime":"0","endTime":"0","summary":"– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 –– Builds on completed Phase 1a study and ongoing development in HDV – SOUTH SAN FRANCISCO, Ca","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3300036/16259/en/Assembly-Biosciences-Announces-Expansion-of-ABI-6250-Clinical-Development-Into-Cholestatic-Liver-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASMB","BK4588","BK4139","PBC","HDV","BK4585","ABI","PSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634864712","title":"Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2634864712","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634864712?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:00","pubTimestamp":1778500800,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., May  11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3291802/16259/en/Assembly-Biosciences-to-Present-at-the-BofA-Securities-2026-Global-Health-Care-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4581","LABU","BK4139","BK4588","HDV","XBI","BK4585","ASMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633176504","title":"Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633176504","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633176504?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:00","pubTimestamp":1778184000,"startTime":"0","endTime":"0","summary":"– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inh","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290491/16259/en/Assembly-Biosciences-Reports-First-Quarter-2026-Financial-Results-and-Recent-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ASMB","BK4588","BK4585","HPI","HDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630391653","title":"Mirum’s brelovitug succeeds in Phase 2b HDV trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2630391653","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630391653?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:31","pubTimestamp":1777293110,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals ( ($MIRM) ) has issued an announcement. On April 27, 2026, Mirum reported that the Phase 2b portion of its AZURE-1 study in c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mirums-brelovitug-succeeds-in-phase-2b-hdv-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mirums-brelovitug-succeeds-in-phase-2b-hdv-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","HDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624520827","title":"Meet the Next Generation of Dividend Aristocrats","url":"https://stock-news.laohu8.com/highlight/detail?id=2624520827","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624520827?lang=en_us&edition=fundamental","pubTime":"2026-04-02 23:30","pubTimestamp":1775143800,"startTime":"0","endTime":"0","summary":"The S&P 500 Dividend Aristocrats Index, known for its defensive traits in tough markets, has lived up to its billing this year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989764664.SGD","LU0170899867.USD","LU1400636491.USD","LU0171293334.USD","LU2433249047.HKD","LU1935042488.USD","LU1066051811.HKD","IE00B3S45H60.SGD","CGDV","LU2430703095.HKD","LU0642271901.SGD","LU2133065610.SGD","SG9999001424.SGD","LU0070217475.USD","SG9999015358.SGD","LU0154236417.USD","LU1551013342.USD","LU0823421416.USD","LU0149725797.USD","LU1032466523.USD","LU0057025933.USD","LU2210149790.SGD","SG9999014880.SGD","LU2023250843.SGD","LU2417539215.USD","BK4598","LU0323591593.USD","LU0784383803.USD","LU2506952097.USD","LU0689472784.USD","LU0354030438.USD","LU1935042215.USD","LU1721428933.USD","LU2023250330.USD","BK4550","BK4519","LU2237443978.SGD","LU2361044865.SGD","LU0345769128.USD","LU0124676726.USD","LU0310799852.SGD","LU0456855351.SGD","LU0256863902.USD","LU1145028129.USD","LU2244417387.USD","LU2471134879.HKD","LU1035773651.USD","LU1935043023.USD","LU0289739343.SGD","LU0080751232.USD","BK4588","LU2168564065.EUR","LU1894683264.USD","BK4554","LU1582987597.SGD","LU2125909593.SGD","LU1153585028.USD","BK4575","SG9999014559.SGD","LU2764263039.SGD","SGXZ99366536.SGD","LU0081259029.USD","IE000ITXATA3.USD","LU1861215975.USD","LU0912757837.SGD","LU0256863811.USD","LU0211328371.USD","LU2456880835.USD","LU1066051225.USD","LU2750360997.AUD","LU2092937221.SGD","LU0444971666.USD","MSFO","LU1691799644.USD","LU2237957811.SGD","LU1721427968.SGD","IE000W1ABFV2.USD","LU1280957306.USD","LU1564329628.SGD","LU2237438978.USD","LU2505996681.GBP","LU1043141396.HKD","LU0320765059.SGD","LU0950375773.USD","LU1989764748.USD","LU1235295455.SGD","LU1400636574.HKD","LU2362541513.USD","LU2347655073.USD","BK4528","LU2543165471.USD","LU1868836591.USD","LU1116320737.USD","LU1670710661.SGD","LU0871640123.AUD","LU2458330169.SGD","LU2237957902.USD","LU2362541273.HKD","LU0689626769.HKD","LU2275660780.HKD","LU0321505439.SGD","LU1043141123.HKD","LU2404859667.USD","HK0000914660.USD","LU0127658192.USD","LU0158827948.USD","LU2756315664.SGD","LU2237443549.SGD","KBWD","SG9999001077.SGD","LU0234570918.USD","IE00BLSP4239.USD","LU2286300806.USD","LU1629891620.HKD","LU1232071149.USD","LU1084165304.USD","LU2360032135.SGD","LU0048584097.USD","LU0320765646.SGD","LU1778281490.HKD","LU1934455863.HKD","LU0861579265.USD","LU2106854487.HKD","LU1929549753.HKD","LU1119994496.HKD","LU1923622614.USD","BK4134","LU1670756490.USD","LU2087625088.SGD","LU0345769631.USD","LU2148611432.USD","LU2471134523.USD","LU0265550946.USD","LU0107464264.USD","LU0312595415.SGD","LU1244550221.USD","IE00B19Z9505.USD","VIGI","DGRW","SDIV","LU0823417653.USD","LU0553294199.USD","LU1697837992.HKD","LU1983260115.SGD","BK4576","LU2250418816.HKD","LU2242650005.HKD","LU1868836757.USD","LU0545562505.USD","LU1236620750.USD","LU1334329650.SGD","LU0095938881.EUR","LU0098860793.USD","LU2087621335.USD","LU2750360641.GBP","LU0787776722.HKD","LU1803068623.USD","LU2065171402.SGD","LU2054465674.USD","BK4538","LMT","IE00BMPRXN33.USD","SG9999014914.USD","IE00BJJMRY28.SGD","LU0444973449.USD","SG9999014567.USD","SG9999018857.SGD","LU1670628061.USD","LU0894485498.HKD","SG9999000418.SGD","BK4525","SG9999001440.SGD","IE00B5TLWC47.USD","IE00BFSS7M15.SGD","LU0096362180.USD","LU0511384066.AUD","LU2430703251.USD","IE00BWXC8680.SGD","MSFY","LU0965509283.SGD","LU0323240290.USD","MSFD","UPS","LU2462157665.USD","LU0234572021.USD","LU1064131342.USD","LU0957791311.USD","MSFX","LU1037948541.HKD","LU2236285917.USD","LU1868836914.USD","LU0894486033.HKD","SGXZ31699556.SGD","LU0724617625.USD","BK4581","LU1883839398.USD","LU1582987324.SGD","IE00BHPRN162.USD","BK4585","SGXZ51526630.SGD","GB00BDT5M118.USD","LU1670711040.USD","LU1951200564.SGD","LU2764262908.HKD","LU1670711123.USD","LU0342679015.USD","LU0823411888.USD","LU1069344957.HKD","LU1791710582.SGD","LU2458330243.SGD","LU0211327993.USD","LU2506952337.HKD","LU1429558221.USD","LU0308772762.SGD","LU2125154778.USD","IE00BK4W5M84.HKD","LU1839511570.USD","LU0006306889.USD","LU1244550577.SGD","LU2089985449.USD","LU0719512351.SGD","LU0128525929.USD","LU1596574779.USD","IE0004445015.USD","IE00B1XK9C88.USD","LU1564329032.USD","IE00BJTD4V19.USD","BK4587","LU2211815571.USD","LU0029864427.USD","LU0162691827.USD","LU0323239441.USD","LU1093756325.SGD","LU1261432733.SGD","LU1267930730.SGD","LU2168564149.EUR","LU0106261372.USD","IE0008368304.USD","LU1181866309.USD","LU0494093205.USD","IE000YTNTUN2.SGD","LU0061475181.USD","LU0949170426.SGD","LU2430703178.SGD","LU1066053197.SGD","SG9999015986.USD","KLAC","LU0266013472.USD","LU1633808545.USD","LU2023250504.SGD","LU2361044949.HKD","LU0426417589.USD","IE00B19Z8W00.USD","LU1989772923.USD","LU1093756168.USD","LU0274383776.USD","LU0417517546.SGD","LU0889565833.HKD","IE0004445239.USD","LU2279689827.SGD","LU0096364046.USD","LU1989772840.SGD","LU2063271972.USD","LU0345774631.USD","LU0198837287.USD","LU1988902786.USD","IE0004091025.USD","LU1069347547.HKD","LU1642822529.SGD","LU1814569148.SGD","LU1852331112.SGD","LU1003077747.HKD","LU1035775433.USD","LU1582986433.USD","LU2413666004.HKD","LU2362540622.SGD","LU0077335932.USD","LU2097829019.USD","LU1032955483.USD","BK4504","LU2360107168.USD","IE00BYQQ9H92.USD","LU1121112475.USD","LU2491049909.HKD","LU2168563687.JPY","LU1430594728.SGD","LU1712237335.SGD","IE00B775H168.HKD","LU1548497426.USD","LU0661504455.SGD","IE00BN29S564.USD","LU2452424414.USD","IE00BBT3K403.USD","LU0072461881.USD","HK0000914686.HKD","LU2746668461.USD","LU1066051498.USD","IE0009G5SDU7.USD","BLK","LU0061474960.USD","LU1989763005.USD","LU1435385759.SGD","LU2097344357.USD","SG9999014575.USD","LU1868837136.USD","LU1074936037.SGD","IE000KEQY171.SGD","IE0005OL40V9.USD","LU1551013425.SGD","LU1674673691.USD","LU2097344431.USD","BK4533","IE0009356076.USD","IE00BQXX3F31.USD","LU1506573853.SGD","LU0056508442.USD","LU0820561818.USD","LU0823434740.USD","LU1221951046.USD","LU2477742899.HKD","LU2298321311.HKD","LU1585245621.USD","LU2290526834.HKD","LU0072462426.USD","SGXZ81514606.USD","DVY","LU0215105999.USD","LU2506951958.HKD","LU0314106906.USD","LU2077746001.SGD","LU2108987350.USD","LU2403377893.USD","SG9999002232.USD","LU0726765562.USD","LU0757359954.USD","BK4592","LU0157215616.USD","LU1235294995.USD","LU0823417737.USD","LU0792757196.USD","BK4534","SG9999014542.SGD","LU0708995401.HKD","IE0034235188.USD","LU0238689110.USD","SPHD","SDY","LU0138981039.USD","LU1732800096.USD","LU1868837300.USD","LU1989773731.SGD","LU2420271590.USD","LU2237443895.HKD","IE0001KFT4U8.USD","IE00BKDWB100.SGD","LU1623119135.USD","LU1917777945.USD","LU1914381329.SGD","BK4612","LU0345770993.USD","LU0353189763.USD","SCHD","FDVV","LU1670710588.SGD","LU1059921491.USD","LU2720916845.USD","LU0210536198.USD","LU0348723411.USD","LU0943347566.SGD","LU1880398554.USD","LU2089284900.SGD","LU0097036916.USD","LU1804176565.USD","LU1791710400.SGD","LU2023251221.USD","LU2264538146.SGD","LU0868494708.USD","DIVO","LU0960925559.SGD","LU0011850046.USD","IE00BMPRXQ63.HKD","LU0289960550.SGD","LU2247934214.USD","IE0003U64NQ7.SGD","LU2491050154.USD","LU0788109477.HKD","BK4535","LU1236620834.HKD","LU2092937148.SGD","IE00BFSS8Q28.SGD","LU0823434583.USD","LU1620156213.USD","IE00BDRTCR15.USD","LU0345768740.USD","LU0820561909.HKD","SG9999002224.SGD","SG9999015978.USD","LU0276348264.USD","BK4527","LU1543694498.USD","LU1645745479.HKD","LU1496350171.SGD","LU2237443465.HKD","BK4503","LU0345774391.USD","LU1823568750.SGD","LU1165135440.EUR","LU1267930573.SGD","MSFU","LU0820562030.AUD","LU0965509101.SGD","LU0965508806.USD","IE00BKPKM429.USD","IE00BYXW3230.USD","LU0310800379.SGD","LU1620156130.USD","LU1316542783.SGD","LU1670627923.USD","LU0353189680.USD","IE00BQXX3C00.GBP","LU1951198990.SGD","LU0210528500.USD","LU1366192091.USD","LU0964807845.USD","LU1196500208.SGD","IE00BSNM7G36.USD","LU1267930490.SGD","LU0868494617.USD","LU1582986359.USD","LU0079474960.USD","LU1935043536.SGD","LU1815336760.USD","LU2065169927.USD","LU0314104364.USD","GB00B4QBRK32.GBP","LU1116320901.HKD","LU0528227936.USD","SGXZ23171101.USD","LU0784385170.HKD","BK4532","IE00B4JS1V06.HKD","LU2237443382.USD","BK4566","IE00BK4W5L77.USD","SG9999015952.SGD","LU2896262040.SGD","LU2552382058.USD","LU0109391861.USD","LU0690374961.EUR","IE00BDCRKT87.USD","BK4602","IE00B1BXHZ80.USD","LU0557290698.USD","LU2552382215.SGD","LU0784385840.USD","LU0354030511.USD","LU0476273544.USD","LU0823421333.USD","LU0949170772.SGD","LU2125909247.SGD","IE00B775SV38.USD","LU2089283258.USD","LU0082616367.USD","LU1861220033.SGD","LU0708994859.HKD","LU0265550359.USD","LU0889566641.SGD","LU1861127337.USD","LU2471134952.CNY","IE00BJLML261.HKD","LU2210150020.SGD","IE00B19Z8X17.USD","LU0690374615.EUR","MSFW","LU1974910355.USD","LU0640476718.USD","LU2357305700.SGD","LU2413666426.HKD","LU1571399168.USD","LU0672654240.SGD","SPYD","LU1267930813.SGD","LU0203202063.USD","LU1496350502.SGD","IE00BN8TJ469.HKD","SG9999017495.SGD","LU0302445910.USD","KLAG","LU2360108059.USD","IE0034235295.USD","LU2413666699.HKD","DGRO","HD","IE00B5949003.HKD","LU2404859741.USD","LU2860962120.EUR","LU0784384876.USD","LU1228905037.USD","LU2041044095.USD","LU2487616109.SGD","LU1934455194.USD","LU2361045086.USD","IE00BJTD4N35.SGD","IE00BLSP4452.SGD","LU1244550494.USD","LU0267386448.USD","QCOM","LU1564329115.USD","LU0957808578.USD","LU2463028550.USD","LU0683600562.USD","LU1340139317.AUD","LU0316494557.USD","LU1803068979.SGD","SG9999018865.SGD","BK4548","BK4579","LU0965509010.AUD","LU0757359368.USD","LU0210533765.USD","LU1935042991.SGD","LU2360106780.USD","LVHI","LU2506951875.HKD","SG9999014906.USD","LU1720051108.HKD","LU0289941410.SGD","IE00B4YYXB79.USD","LU0426412945.USD","LU0879622024.SGD","LU0882574139.USD","IE00BZ1G4Q59.USD","LU0175139822.USD","BK4577","IE00B7KXQ091.USD","LU0225283273.USD","IE00BMPRXR70.SGD","LU1934455277.USD","BK4543","LU2592432038.USD","TXN","LU0094547139.USD","LU0321505868.SGD","LU0738911758.USD","SG9999014898.SGD","LU0187121727.USD","LU0109392836.USD","LU0994945656.USD","LU2092627202.USD","LU2602419157.SGD","SG9999015341.SGD","LU1127390331.HKD","LU0985320562.USD","LU0545039389.USD","LU2413665964.HKD","IE00B3SWFQ91.USD","LU0795875169.SGD","BK4083","LU2168564495.EUR","LU1923623000.USD","SG9999004303.SGD","LU0251132253.USD","LU2505996509.AUD","LU2491050071.SGD","LU1202635105.USD","LU2326559502.SGD","LU1674673428.USD","LU2237443622.USD","LU2242649171.HKD","IE00BKVL7J92.USD","LU1221951129.SGD","LU0289961442.SGD","IE00BQXX3D17.EUR","LU2461242641.AUD","LU1323610961.USD","LU1815333072.USD","LU0203201768.USD","LU0069063385.USD","LU1037948897.HKD","BK4097","LU2095319765.USD","LU1880398471.USD","LU2381873111.SGD","LU0061474705.USD","IE0034235303.USD","LU1188199696.SGD","LU0795875086.SGD","LU1366333091.USD","LU0345770308.USD","LU2065171311.SGD","LU1564329461.SGD","LU2083900584.USD","LU2746668974.SGD","LU0158827781.USD","BK4516","LU2168564222.USD","IE00BFXG0V08.USD","LU2028103732.USD","GB00B4LPDJ14.GBP","LU2471134796.USD","LU0053666078.USD","LU2265009873.SGD","LU0347712357.USD","LU1718418525.SGD","LU0942090050.USD","IE0004086264.USD","LU2191332357.HKD","LU0390134368.USD","LU1732799900.SGD","LU2764263203.CNY","LU1720051017.SGD","MSFT","LU1228905540.USD","LU2111349929.HKD","IE00BJJMRX11.SGD","LU1162221912.USD","LU0472753341.HKD","LU2065170008.USD","LU2506952170.USD","LU2213496289.HKD","BK4147","LU2552382132.HKD","LU1400636657.SGD","LU2125154935.USD","LU1046421795.USD","MSFL","LU2271345857.HKD","BK4567","LU0345768153.USD","LU1721428347.USD","SG9999015945.SGD","LU2756315318.SGD","LU1894683348.USD","LU1301847155.USD","LU2506952410.USD","LU0466842654.USD","LU2347655156.SGD","HDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623391633","title":"The Iran War Could Drag On. Where Investors Are Finding Winners Now. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2623391633","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623391633?lang=en_us&edition=fundamental","pubTime":"2026-03-30 15:00","pubTimestamp":1774854000,"startTime":"0","endTime":"0","summary":"The Nasdaq is in a correction, down more than 10% from its recent highs. And there are growing worries that the tech-heavy index could soon find itself in a bear market -- a drop of 20%. But you know what they say on Wall Street: There's always a bull market somewhere.Even though the broader market has pulled back in the past few days, extending their weekly losing streak to five, there were pockets of strength this past week -- and for the whole month of March, for that matter.Another legacy tech firm, albeit once trading at a much higher multiple than Dell and HPE, is also getting an AI boost. Shares of glass and optical networking leader Corning were up nearly 10% on the back of a bullish analyst report from BofA Securities. At more than 40 times earnings estimates, Corning isn't cheap. But like Dell and HPE, it's viewed as a winner in a world where tech spending isn't about to collapse anytime soon.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","BK4148","HPE","LU0225771236.USD","LU0345781412.USD","LU0265550946.USD","LU0278409577.USD","SG9999002521.SGD","GLW","LU0006061336.USD","LU1883839398.USD","SMCC","LU2129689431.USD","LU0345770993.USD","LU2272731865.HKD","LU0208291251.USD","IE00B19Z3B42.SGD","BK4135","LU0122376428.USD","BK4170","LU0321505868.SGD","LU0256863811.USD","SMCL","LU0417517546.SGD","LU0868494708.USD","SMCX","IE00BFMHRM44.USD","SMYY","ISBC","BK4512","LU2272731782.SGD","LU0265550359.USD","IE000M9KFDE8.USD","CVX","LU0612318971.USD","SMCY","LU1929549753.HKD","HDV","LU0612318385.USD","LU0061475181.USD","LU0985481810.HKD","LU1280957306.USD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU2129689605.HKD","SMCZ","LU0098860793.USD","STT","LU1861215975.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620276128","title":"Press Release: Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276128","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620276128?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:05","pubTimestamp":1773950700,"startTime":"0","endTime":"0","summary":"-- Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipated by mid-2026 --. -- Phase 2 initiation for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus, anticipated by end of 2026 --. SOUTH SAN FRANCISCO, Calif., March 19, 2026  -- Assembly Biosciences, Inc. , a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the year ended December 31, 2025, and recent highlights.\"2025 was a pivotal year for the Company, and we anticipate another strong year ahead,\" said Jason Okazaki, chief executive officer and president of Assembly Bio. \"Compelling Phase 1b data across ABI-5366 and ABI-1179 led to an early decision by Gilead to license the HPI program, validating the strength of our science and execution, as well as the poten","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","ASMB","BK4232","BK4588","HDV","R","BK4139","HPI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618964945","title":"Retiring Soon? Why the HDV ETF Beats DVY for Steady 2026 Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2618964945","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618964945?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:21","pubTimestamp":1773224475,"startTime":"0","endTime":"0","summary":"Income investors are constantly looking for ways to boost their portfolio’s cash flow without taking on unnecessary risk. Two of the most popular t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/retiring-soon-why-the-hdv-etf-beats-dvy-for-steady-2026-income?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/retiring-soon-why-the-hdv-etf-beats-dvy-for-steady-2026-income?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","FDN","DVY","HDV","BK4585","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617659329","title":"DGRO vs. HDV: Which BlackRock iShares Dividend ETF Pays More Income?","url":"https://stock-news.laohu8.com/highlight/detail?id=2617659329","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617659329?lang=en_us&edition=fundamental","pubTime":"2026-03-07 08:30","pubTimestamp":1772843418,"startTime":"0","endTime":"0","summary":"Investors looking for dividend income often compare BlackRock’s ($BLK) iShares Core Dividend Growth ETF ($DGRO) and iShares Core High Dividend ETF ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/dgro-vs-hdv-which-blackrock-ishares-dividend-etf-pays-more-income?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/dgro-vs-hdv-which-blackrock-ishares-dividend-etf-pays-more-income?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1599440770.SGD","BK4581","LU1064131342.USD","LU2264538146.SGD","LU1280957306.USD","LU1481011671.HKD","LU0742537680.HKD","BLK","LU0980610538.SGD","LU0130102774.USD","BK4588","LU0070302665.USD","BK4533","LU1670628061.USD","FDN","LU1291159041.SGD","SCHD","LU0640476718.USD","LU1074936037.SGD","IE00B3QW5Z07.USD","LU0320765489.SGD","LU2505996681.GBP","BK4534","IE00B64PRP62.GBP","IE00BGHQF631.EUR","LU1988902786.USD","LU0157215616.USD","LU1481011911.USD","BK4550","IE00BVYPNV92.GBP","LU0648001328.SGD","BK4535","IE00BDGV0183.EUR","IE00B42XCP33.USD","IE00BVYPNW00.USD","LU1201861249.SGD","LU2430703251.USD","LU0772969993.USD","BK4504","BK4135","LU0731783394.SGD","HDV","LU0731783048.USD","BK4567","LU1989771016.USD","LU1509826696.USD","IE00BGHQF748.EUR","DGRO","LU2430703178.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610851608","title":"DGRO, DVY, and HDV: 3 iShares Dividend ETFs to Watch Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2610851608","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610851608?lang=en_us&edition=fundamental","pubTime":"2026-02-11 08:11","pubTimestamp":1770768691,"startTime":"0","endTime":"0","summary":"BlackRock’s ($BLK) iShares lineup offers several ways to earn dividend income, but not all dividend ETFs are built the same. The iShares Core Divid...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/dgro-dvy-and-hdv-3-ishares-dividend-etfs-to-watch-now?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/dgro-dvy-and-hdv-3-ishares-dividend-etfs-to-watch-now?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DVY","BK4581","LU0130102774.USD","LU1670628061.USD","IE00BGHQF748.EUR","LU1481011671.HKD","LU0980610538.SGD","LU2505996681.GBP","BK4533","IE00BVYPNW00.USD","LU1280957306.USD","LU1988902786.USD","BK4535","LU0648001328.SGD","HDV","IE00B3QW5Z07.USD","IE00BVYPNV92.GBP","LU1670627923.USD","LU2430703178.SGD","LU1366333091.USD","LU1481011911.USD","BLK","LU1599440770.SGD","IE00B3PB1722.GBP","LU1989771016.USD","LU0320765489.SGD","SCHD","LU1201861249.SGD","LU0070302665.USD","LU0731783394.SGD","LU1509826696.USD","LU0731783048.USD","LU2430703251.USD","BK4567","LU0157215616.USD","LU1064131342.USD","LU0640476718.USD","BK4585","BK4504","BK4534","IE00B64PRP62.GBP","LU2505996509.AUD","DGRO","BK4135","LU0772969993.USD","LU2592432038.USD","IE00BDGV0183.EUR","IE00BGHQF631.EUR","LU1291159041.SGD","IE00B42XCP33.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606209062","title":"Libevitug Approved in China as First-in-Class Hepatitis D Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2606209062","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606209062?lang=en_us&edition=fundamental","pubTime":"2026-01-27 16:15","pubTimestamp":1769501700,"startTime":"0","endTime":"0","summary":"BEIJING, Jan. 27, 2026 /PRNewswire/ -- Huahui Health announced that China's National Medical Products Administration  has granted conditional approval to its Libevitug injection for chronic hepatitis D virus  infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of hepatitis B virus  and HDV envelope proteins, blocking viral entry into hepatocytes. As a groundbreaking advance in viral hepatitis care, it is China's first approved HDV therapy and a first-in-class antibody for viral hepatitis, addressing a critical clinical gap.According to the World Health Organization , HDV affects nearly 5%  of people with chronic HBV infection. HDV–HBV co-infection is considered the most severe form of chronic viral hepatitis due to more rapid progression towards hepatocellular carcinoma and liver-related death.","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2870372/image1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2870372/image1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/libevitug-approved-in-china-as-first-in-class-hepatitis-d-treatment-302670977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1878469433.USD","BK4139","BK4599","HDV","BK4585","ALT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603635736","title":"Vir Biotechnology: Strengthening Best-in-Class HDV Profile with Robust SOLSTICE Data, Strategic Partnerships, and Sufficient Cash Runway Supporting Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2603635736","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603635736?lang=en_us&edition=fundamental","pubTime":"2026-01-13 23:46","pubTimestamp":1768319170,"startTime":"0","endTime":"0","summary":"Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Vir Biotechnology. The associated price target remains the same wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/vir-biotechnology-strengthening-best-in-class-hdv-profile-with-robust-solstice-data-strategic-partnerships-and-sufficient-cash-runway-supporting-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/vir-biotechnology-strengthening-best-in-class-hdv-profile-with-robust-solstice-data-strategic-partnerships-and-sufficient-cash-runway-supporting-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HDV"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://us.ishares.com/product_info/fund/overview/HDV.htm","stockEarnings":[{"period":"1week","weight":0.0073},{"period":"1month","weight":0.0158},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1235},{"period":"1year","weight":0.1747},{"period":"ytd","weight":0.136}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":-0.0006},{"period":"3month","weight":0.114},{"period":"6month","weight":0.0821},{"period":"1year","weight":0.2268},{"period":"ytd","weight":0.0819}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.010049},{"month":2,"riseRate":0.733333,"avgChangeRate":0.010665},{"month":3,"riseRate":0.666667,"avgChangeRate":0.002721},{"month":4,"riseRate":0.6875,"avgChangeRate":0.016755},{"month":5,"riseRate":0.625,"avgChangeRate":0.001199},{"month":6,"riseRate":0.5,"avgChangeRate":-0.002147},{"month":7,"riseRate":0.8,"avgChangeRate":0.017565},{"month":8,"riseRate":0.466667,"avgChangeRate":-0.002403},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.015253},{"month":10,"riseRate":0.533333,"avgChangeRate":0.015506},{"month":11,"riseRate":0.8,"avgChangeRate":0.025417},{"month":12,"riseRate":0.466667,"avgChangeRate":-0.005302}],"exchange":"ARCA","name":"iShares Core High Dividend ETF","nameEN":"iShares Core High Dividend ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"iShares Core High Dividend ETF(HDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest iShares Core High Dividend ETF(HDV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"iShares Core High Dividend ETF,HDV,iShares Core High Dividend ETF股票,iShares Core High Dividend ETF股票老虎,iShares Core High Dividend ETF股票老虎国际,iShares Core High Dividend ETF行情,iShares Core High Dividend ETF股票行情,iShares Core High Dividend ETF股价,iShares Core High Dividend ETF股市,iShares Core High Dividend ETF股票价格,iShares Core High Dividend ETF股票交易,iShares Core High Dividend ETF股票购买,iShares Core High Dividend ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"iShares Core High Dividend ETF(HDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest iShares Core High Dividend ETF(HDV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}